The pharma industry is moving on from merely broadcasting on social platforms and starting to listen and engage, appreciating the benefits of mining these rich seams of data.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh